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Hydroxymethylglutaryl Coenzyme-A
Reductase Inhibitors Delay the Progression
of Rheumatic Aortic Valve Stenosis
A Long-Term Echocardiographic Study
Francesco Antonini-Canterin, MD,* Elisa Leiballi, MD,* Roxana Enache, MD,†
Bogdan A. Popescu, MD, PHD,†‡ Monica Ros¸ca, MD,† Eugenio Cervesato, PHD,* Rita Piazza, MD,*
Carmen Ginghina˘, MD, PHD,†‡ Gian Luigi Nicolosi, MD*
Pordenone, Italy; and Bucharest, Romania
Objectives This study sought to assess the effect of hydroxymethylglutaryl coenzyme-A reductase inhibitors (statins) on the
progression of rheumatic aortic valve stenosis.
Background The possible role of statins in slowing the progression of degenerative aortic valve stenosis (AS) is still debated.
No information about the role of statin treatment in patients with rheumatic AS is available yet.
Methods From our 1988 to 2008 echocardiographic database, we retrospectively identified all patients with rheu-
matic AS, with a baseline peak aortic velocity 1.5 m/s and at least 2 echocardiographic studies 2 years
apart. Exclusion criteria were: severe aortic regurgitation, bicuspid aortic valve, and left ventricular ejection
fraction 40%.
Results The study population consisted of 164 patients (30 treated with statins) followed up for 8.5  4.2 years. Peak
aortic velocity at baseline was not different in patients treated with statins versus untreated patients (2.3  0.8
m/s vs. 2.3  0.7 m/s, p  0.84). There were no significant differences in sex, age, or follow-up duration be-
tween the 2 groups. Progression of AS severity was slower in patients receiving statins compared with untreated
patients (annual change of peak aortic velocity: 0.05  0.07 m/s/year vs. 0.12  0.11 m/s/year, p  0.001).
An annual rate of peak velocity progression 0.1 m/s was found in 10% of statin-treated patients and in 49% of
untreated patients (p  0.0001).
Conclusions This is the first observation of a positive effect of statin treatment in reducing the progression of rheumatic AS.
The underlying mechanisms remain to be clarified. (J Am Coll Cardiol 2009;53:1874–9) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.064e
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sheumatic heart disease still represents a major public heart
roblem, especially in developing countries (1–4). Even if
uring the last decades the prevalence of rheumatic heart
isease has greatly decreased in industrialized countries,
ecently, because of increasing migration of people from
See page 1880
reas where rheumatic heart disease is still endemic, we
ncounter again patients with rheumatic heart disease in our
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008, accepted January 5, 2009.chocardiographic laboratories. Echocardiography repre-
ents the gold standard imaging technique in patients with
uspected or known rheumatic heart disease (2–5). It is well
nown that nowadays the degenerative etiology of aortic
alve disease is the most prevalent one, but there are still
ases of rheumatic aortic valve disease, mostly aortic regur-
itation but also aortic stenosis (AS). The hypothesis that
tatin treatment could slow the progression of degenerative
ortic valve stenosis is still controversial (6), and the recent
EAS (Simvastatin and Ezetimibe in Aortic Stenosis) study
id not show any benefit of statins plus ezetimibe in reducing
S progression (7). However, information about the role of
tatins in patients with rheumatic AS is not yet available.
herefore, the goal of this study was to assess the effect of
tatin treatment on the long-term hemodynamic progression
f AS in a large group of patients with rheumatic heart disease.
MS
o
p
(
r
f
a
w
v

p
v
r
t
g
o
C
a
c
(
l
d
a
d
c
m
r
a
E
p
b
e
e
p
a
P
d
A
a
l
v
l
t
A
m
w
r
o
v
S
a
c
v
v
s
d
p
a
s
T
v
R
T
a
w
(
p
m
d
b
b
h
c
T
p
P
V
1875JACC Vol. 53, No. 20, 2009 Antonini-Canterin et al.
May 19, 2009:1874–9 Statins in Rheumatic Aortic Valve Stenosisethods
tudy population. A systematic retrospective analysis of
ur adult echocardiography computerized database was
erformed. All patients examined over the last 20 years
between 1988 and 2008) who were found to be affected by
heumatic heart disease (confirmed history of rheumatic
ever and/or classical signs of rheumatic mitral valve disease
nd typical echocardiographic aspect of the aortic valve)
ere selected. All patients who had a baseline peak aortic
elocity 1.5 m/s and at least 2 echocardiographic studies
2 years apart were considered for the study. Patients with
revious aortic valve surgery, bicuspid aortic valves, reduced left
entricular function (ejection fraction 40%), severe aortic
egurgitation, symptoms at first examination, or lack of de-
ailed information on medical therapy were excluded. Demo-
raphic, clinical, and laboratory data (when available) were
btained by review of the patient’s medical records.
linical data. The following clinical data were collected:
ge, sex, history of hypertension, diabetes mellitus, hyper-
holesterolemia, prior evidence of coronary artery disease
CAD) (history of myocardial infarction, coronary revascu-
arization, or CAD by angiography) and end-stage renal
isease requiring dialysis. Information regarding medication
nd specifically the use of statin treatment (type of drug,
ose, and treatment duration), was also obtained. We
onsidered a patient to be statin treated only if the infor-
ation about statin treatment was present in serial medical
ecords during the entire follow-up period (between the first
nd the last available echocardiographic examination).
chocardiographic examination. Echocardiography was
erformed with commercially available ultrasound systems
y experienced staff cardiologists. Interpretation of the
chocardiographic studies was conducted without knowl-
dge of the present study. All patients underwent a com-
rehensive examination, including 2-dimensional, pulsed-
nd continuous-wave, and color Doppler echocardiography.
eak velocity, peak instantaneous gradient, and mean gra-
ient across the aortic valve were measured according to the
merican Society of Echocardiography guidelines (8).
atient Characteristics in the Whole Population and in the 2 Group
Table 1 Patient Characteristics in the Whole Population and in
Variable All Patients (n  164)
Female sex 126 (76.8)
Age (yrs) 61 10
Baseline peak aortic velocity (m/s) 2.3 0.73
Baseline peak aortic gradient (mm Hg) 23.4 16.8
Baseline LV ejection fraction (%) 56.9 7
Final LV ejection fraction (%) 54.4 9
Coronary artery disease 21 (12.8)
Hypercholesterolemia 48 (29.3)
Hypertension 65 (39.6)
Diabetes mellitus 24 (14.6)
Follow-up (yrs) 8.5 4.2alues are n (%) or mean  SD.
LV  left ventricular; statin   untreated patients; statin   statin-treated patients.The primary end point was the
nnual change in peak aortic ve-
ocity (m/s/year) calculated by di-
iding the difference between the
ast and the first measurements by
he time between examinations.
nnualized changes in peak and
ean gradients (mm Hg/year)
ere also calculated. In our labo-
atory, the interobserver coefficient
f reproducibility (9) for recording and measuring peak aortic
elocity, in a group of 50 patients, was 0.20 m/s.
tatistical analysis. Continuous variables were expressed
s mean  SD and categorical variables as percentages. The
hi-square test was used for the comparison of dichotomous
ariables, and the Student t test was used for continuous
ariables. A value of p  0.05 was considered statistically
ignificant. A multiple linear regression analysis was used to
etermine the independent predictors of AS hemodynamic
rogression. The variables introduced in the analysis were:
ge, sex, hypercholesterolemia, diabetes, CAD, hyperten-
ion, baseline peak aortic velocity, and use of statin therapy.
he analyses were performed using SPSS for Windows,
ersion 13.0 (SPSS Inc., Chicago, Illinois).
esults
he final study population consisted of 164 patients (mean
ge 61  10 years, 126 women), 30 of which were treated
ith statins. Mean follow-up duration was 8.5  4.2 years
range 2 to 20 years). Hypertension was present in 65
atients (40%), hypercholesterolemia in 48 (29%), diabetes
ellitus in 24 (15%). Only 1 patient was undergoing
ialysis. There were no significant differences in sex distri-
ution, age, and follow-up duration between the 2 groups
ut, as expected, the prevalence of hypercholesterolemia was
igher in the statin group (Table 1). Echocardiographic
haracteristics at baseline and at follow-up are shown in
able 1. Peak aortic velocity at baseline was similar in
atients treated with statins versus untreated patients (2.3
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AS  aortic stenosis
CAD  coronary artery
disease
CRP  C-reactive protein
atin-Treated Patients and Untreated Patients
2 Groups: Statin-Treated Patients and Untreated Patients
Statin  (n  134) Statin  (n  30) p Value
101 (75%) 25 (83%) 0.57
61 10 60 10 0.85
2.3 0.72 2.3 0.76 0.84
23.2 16.9 23.9 17 0.26
56.5 6.7 58.9 8.3 0.099
54.4 8.7 54.2 10.2 0.913
14 (10.4) 7 (23) 0.056
21 (15.6) 27 (90) 0.001
53 (39.5) 12 (40) 0.096
20 (14.9) 4 (13.3) 0.824
8.6 4.5 8.4 4.2 0.967s: St
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Statins in Rheumatic Aortic Valve Stenosis May 19, 2009:1874–9.8 m/s vs. 2.3  0.7 m/s, p  0.84). No patient had more
han mild AS at baseline. Progression of AS severity was
lower in patients receiving statins compared with untreated
atients (annual change in peak aortic velocity: 0.05  0.07
/s/year vs. 0.12  0.11 m/s/year, p  0.001) (Fig. 1). The
bsolute change in peak aortic velocity between baseline and
ast follow-up was higher in untreated patients compared
ith patients treated with statins (Fig. 2). A fast AS
rogression was defined as an annual rate of peak aortic
elocity progression  0.1 m/s. Fast AS progression was
ound in 10% of statin-treated patients and in 49% of
ntreated patients (p  0.0001) (Fig. 3).
At multivariate analysis (including age, sex, hypercho-
esterolemia, diabetes mellitus, CAD, hypertension,
aseline peak aortic velocity, and statin therapy) only
tatin therapy (p  0.001) and baseline peak aortic
elocity (p  0.001) were independently related to
heumatic AS progression.
During follow-up, worsening of aortic regurgitation
1 degree/3) was found in 17% of statin treated patients
nd in 19% of untreated patients (p  0.93). An analysis
f statin treatment effect on mitral valve stenosis was not
ossible because of the large number of previous surgical
r interventional procedures performed on the mitral
alve.
The statins used and the mean  SD daily dosages were:
imvastatin, 10 patients (18  9.2 mg); atorvastatin, 14
Figure 1 Progression Rate of Rheumatic Aortic Stenosis
Progression of rheumatic aortic stenosis, expressed as the annualized rate of
peak aortic velocity changes (unadjusted values, m/s/year), shown in statin-
treated (statin ) and in untreated (statin ) patients (p  0.0001).atients (15  8.5 mg); pravastatin, 3 patients (23  15.3g); fluvastatin, 1 patient (40 mg); rosuvastatin, 2 patients
10  0 mg).
With similar distribution in the statin and nonstatin
roups, 67 patients (41%) were treated with angiotensin-
onverting enzyme inhibitors (ACEIs). The use of ACEIs
id not influence progression of rheumatic AS (rates of peak
ortic velocity progression were 0.09  0.11 m/s/year in
atients treated with ACEIs and 0.11  0.11m/s/year in
ntreated patients, p  0.44).
iscussion
heumatic heart disease is a major public health problem in
eveloping countries. Up to 1% of school children in Africa,
sia, the Eastern Mediterranean region, and Latin America
how signs of this disease. It has been estimated that
orldwide 15.6 million people are affected by rheumatic
eart disease, and every year there are about 470,000 new
ases of rheumatic fever and 233,000 deaths attributable to
heumatic heart disease (1–3). There are about 2 million
eople with rheumatic heart disease requiring repeated
ospitalization, and 1 million are likely to require surgery
lobally (4). However, these estimates are based on conser-
ative assumptions. In recent echocardiographic studies the
revalence of aortic valve involvement in rheumatic valve
isease ranged between 5% and 24% in developing countries
10,11). The prevalence of rheumatic heart disease in
eveloped countries decreased during the last decades. The
ost common cause of AS in adults is calcification of a
ormal trileaflet or congenital bicuspid valve. This calcific
Figure 2 Changes in Peak Aortic Velocity
During Follow-Up in Rheumatic Aortic Stenosis
Changes in absolute (unadjusted) values of peak aortic velocity (m/s) during
follow-up, shown in statin-treated (statin ) and in untreated (statin )
patients (p  0.02).
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May 19, 2009:1874–9 Statins in Rheumatic Aortic Valve Stenosisisease progresses from the base of the cusps to the leaflet
argins, eventually causing a reduction in leaflet mobility
nd effective valve area, without commissural fusion. Rheu-
atic AS caused by fusion of the commissures with scarring
nd calcification of the cusps is less common and is
nvariably accompanied by mitral valve disease (12). Now-
days, although degenerative AS is the most prevalent form
f aortic valve diseases, cases of rheumatic AS are still
resent in our echocardiographic laboratories. Echocardiog-
aphy represents the gold standard imaging technique in
atients with suspected or known rheumatic heart disease
2,5). Typical aspects of aortic valve involvement in rheu-
atic valve disease are represented by adhesions and fusions
f the commissures, cusp retraction, and stiffening of the
ree borders of the cusps (13). These macroscopic features
re the result of the pathogenic mechanism: autoimmune
umoral and cellular responses directed toward the cardiac
tructure, triggered by the response to beta-hemolytic group
streptococci. The precise pathogenic mechanisms of
heumatic heart disease have never been clearly defined. It
as been postulated that chronic rheumatic valve disease is
sually the result of repeated episodes of carditis and is
haracterized by deposition of fibrous tissue. The debate
ontinues about whether the anatomical changes in chronic
heumatic valve disease result from a smoldering rheumatic
rocess or, once the valve has been deformed by turbulent
ow, this leads to progressive fibrosis, thickening, and
alcification (14). Recent studies indicate that calcification is
ot merely an inactive process but involves a regulated
nflammatory process associated with expression of osteo-
Figure 3 Prevalence of Rheumatic
Aortic Stenosis Progression Patterns
Percent of patients with a fast progression pattern (annual rate of increase in
peak aortic velocity 0.1 m/s/year, solid bars) and of patients with slower
aortic stenosis progression (annual rate of increase in peak aortic velocity
0.1 m/s/year, open bars) in statin-treated (statin ) and in untreated (statin
) patients (p  0.0001 for both progression patterns).last markers and neoangiogenesis. Also, inflammatory iytokines have been involved as mediators in the immune
esponse in rheumatic aortic valve disease (15). Recent data
uggest that oxidative stress and high-sensitivity C-reactive
rotein (CRP) plasma levels as a marker of systemic
nflammation could be involved in the pathogenesis of
heumatic valve disease (16,17). Therefore, the role of
nflammation in rheumatic valve disease progression should
e considered. Indeed, the persistence of high levels of
igh-sensitivity CRP has been shown in patients with
hronic rheumatic valve disease, particularly in patients with
ultivalvular disease, who showed significantly higher
lasma levels of CRP (18).
Degenerative AS is no longer considered an unmodifiable
rocess, but rather an active, atherosclerosis-like inflamma-
ory process (19). Thus, it was reasonable to hypothesize
hat pharmacological strategies effective in atherosclerosis,
uch as statin treatment, might also be an effective therapy
n AS. This hypothesis has been tested in several studies
20–25), with either positive or negative results. Some
etrospective studies have shown that statin use may be
ssociated with a decreased rate of degenerative AS progres-
ion (20–23). Similar results were also obtained in a recent
rospective open-label study (RAAVE [Rosuvastatin Af-
ecting Aortic Valve Endothelium] trial) (24). However, the
double-blind randomized controlled trials (the SALTIRE
Scottish Aortic Stenosis and Lipid Lowering Therapy,
mpact on Regression] and SEAS [Simvastatin and
zetimibe in Aortic Stenosis] trials) failed to show a benefit
f intensive lipid-lowering therapy on calcific AS progres-
ion (7,25). The SEAS study involved 1,873 patients with
ild to moderate asymptomatic AS (peak aortic velocity
etween 2.5 and 4 m/s) who received either 40 mg of
imvastatin plus 10 mg of ezetimibe or placebo daily. The
rial, having a median follow-up of 52.2 months, concluded
hat intensive lipid lowering did not reduce AS progression,
ut as expected, it reduced the incidence of ischemic events
7). In a very recent retrospective study assessing the
ong-term impact of statin treatment on degenerative AS
rogression in 1,046 patients, we have shown a positive
ffect of statins in patients with aortic valve sclerosis and
ild AS, but not in moderate to severe AS (26), suggesting
hat early treatment could be more effective. The benefit of
tatin treatment in slowing the progression of degenerative AS
ould be related to both its lipid- and nonlipid-lowering effects,
ncluding anti-inflammatory properties (27), especially through
RP lowering (28), partial inhibition of cellular proliferation
29), or improvement in endothelial function (30) and reduc-
ion of the oxidative processes (28).
The present study is the first one analyzing the possible
ffect of statin treatment in rheumatic valve disease. Cur-
ently, the treatment of chronic rheumatic heart disease is
ainly directed at preventing acute attacks of rheumatic
ever, but there is no specific treatment aimed at preventing
he progression of valvular damage. The high level of CRP
n the chronic phase raises the idea of using anti-
nflammatory therapy (18). It has been suggested that
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Statins in Rheumatic Aortic Valve Stenosis May 19, 2009:1874–9tatins may inhibit the inflammatory and noninflammatory
rocesses that induce the acute phase response, and are thus
ble to reduce CRP levels (31). Furthermore, CRP levels
ere found to be increased in patients with chronic degen-
rative AS (32) and degenerated bioprosthesis (33). Skow-
sch et al. (33) suggested that serum CRP concentrations
ay reflect inflammatory processes within the aortic valve.
ecause statins have not only cholesterol-lowering proper-
ies but also pleiotropic and anti-inflammatory properties,
he use of statins may be useful for preventing degeneration
f native aortic valve and bioprosthesis.
In view of these facts, the hypothesis that statin treatment
ould also be beneficial in rheumatic AS is a sound one. Our
tudy tested this hypothesis retrospectively in a group of
atients with documented rheumatic valve disease, dividing
he study population into 2 groups (with or without statin
reatment) and assessing the impact of statins on AS
rogression (increase in peak aortic velocity) during long-
erm follow-up. The study protocol is similar to those used
n previous retrospective studies on the role of statins in
egenerative AS (20–23,26).
The 2 groups were similar with respect to age, sex,
revalence of hypertension, diabetes mellitus, CAD, and
aseline echocardiographic parameters of AS severity,
hich was mild in both groups at baseline (Table 1). As
xpected, the prevalence of hypercholesterolemia was sig-
ificantly higher in the statin group. Our results showed a
ignificant difference between groups regarding annual
hange in peak aortic velocity and overall change in velocity
etween baseline and last follow-up (Figs. 1 and 2). In
ddition, a pattern of fast progression was found in un-
reated patients more frequently than in statin-treated
atients. Usually, in degenerative AS a pattern of fast
rogression is considered to be present when the annual
hange in peak aortic velocity is 0.3 m/s/year (34).
ecause the velocity of AS progression is lower in rheumatic
S, we chose a cutoff of 0.1 m/s/year for identifying fast
rogression, and a significant difference between statin-
reated and untreated patients was noted (Fig. 3). These
esults are similar to those recently reported by our group
26) showing that statins slow the progression of aortic valve
clerosis and mild AS.
tudy limitations. This study has the inherent limitations
f a retrospective, observational study. However, we tried to
educe the potential sources of selection bias by including a
arge number of patients for this particular etiology and by
aving a long-term follow-up.
For the lack of complete aortic valve area measurements
as a consequence of the retrospective nature of the study
nd of the inclusion of patients with mild disease [peak
ortic jet velocity 1.5 m/s]), we only analyzed peak aortic
et velocity for assessing aortic valve disease progression.
evertheless, peak aortic jet velocity is a well-validated and
idely used parameter of AS severity in the absence of
ignificant left ventricular dysfunction (as is the case in our
tudy). This measurement also shows a lower variabilityhen compared with other measures of AS severity. In our
tudy, both initial and final ejection fractions were similar in
he 2 groups (treated and untreated patients); therefore, we
elieve this factor does not influence our results. Complete
nformation regarding the lipid profiles of these patients was
ot available. Therefore, we could not analyze the possible
elationship between changes in lipid profile and aortic
isease progression.
onclusions
his is the first study to assess the role of statin treatment in
atients with rheumatic AS. It provides evidence for a
ositive effect of statins in reducing the progression of
heumatic AS. These findings may have important impli-
ations for the early management of this progressive disease.
he underlying mechanisms, not yet fully understood,
emain to be clarified.
eprint requests and correspondence: Dr. Francesco Antonini-
anterin, Cardiologia, ARC, Azienda Ospedaliera S. Maria degli
ngeli, Via Montereale 24, 33170 Pordenone, Italy. E-mail:
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